Clinical Ink and Tandem Diabetes Care Partner to Revolutionize Type 1 Diabetes Clinical Trials with Automated Data Integration
Table of Contents
A new collaboration between Clinical Ink and Tandem Diabetes Care (Nasdaq: TNDM) promises to significantly improve the efficiency and accuracy of automated insulin delivery (AID) data collection in clinical trials for type 1 diabetes. The partnership integrates Tandem’s advanced insulin pump systems with Clinical Ink’s GlucoseReady platform, automating a process traditionally reliant on manual reporting.
The integration addresses a critical need for streamlined data capture in diabetes research, offering a more reliable and patient-centric approach to clinical trials. This advancement is poised to accelerate the development of new therapies and improve outcomes for individuals living with type 1 diabetes.
Streamlining Clinical Trials with Automated Data Capture
The core of the collaboration lies in the seamless connection between Tandem’s t:slim X2 and Mobi AID systems and Clinical Ink’s GlucoseReady platform. This integration allows for the secure and automated recording of basal and bolus insulin data directly from patients’ insulin pumps. Participants who voluntarily enroll in a study will have their data transmitted directly into the GlucoseReady platform, eliminating the burden of manual logging.
According to a company release, the data collected can be blinded to participants while remaining accessible to trial sponsors, ensuring both patient privacy and research integrity. This capability complements GlucoseReady’s existing functionalities, which already include capturing data from continuous glucose monitoring (CGM) systems, blood glucose monitoring (BGM), and other digital biomarkers.
Enhancing Data Integrity and Patient Experience
The move towards automated data collection is expected to have a profound impact on the quality and reliability of clinical trial data. By reducing reliance on manual reporting, the companies aim to minimize errors and improve data integrity. This, in turn, will streamline trial workflows and enhance the overall patient experience.
“Our partnership with Tandem Diabetes Care represents a significant step forward in the evolution of clinical trials in type 1 diabetes,” stated a senior official from Clinical Ink. “By combining insulin delivery data with CGM and patient-reported outcomes in a single GCP-compliant platform, we enable sponsors to achieve additional transparency and accuracy. This integration strengthens patient engagement and retention, both of which are important in type 1 diabetes.”
Setting a New Precedent for Diabetes Research
Tandem Diabetes Care also expressed enthusiasm for the collaboration, highlighting its potential to advance the field of diabetes research. “We are pleased to be working with Clinical Ink on this initiative,” said a company spokesperson. “This collaboration sets a new precedent for type 1 diabetes research, and we are proud to see our market-leading advanced insulin delivery systems represented as part of this effort.”
The integration is expected to not only improve the efficiency of clinical trials but also support regulatory compliance by providing a robust and auditable data trail. This advancement signifies a commitment to innovation and a shared vision for a future where diabetes research is more accurate, efficient, and patient-focused.
